Black Diamond Therapeutics (BDTX) Event Aug. 09, 2022, 00:00 UTC (28% Negative) BLACK DIAMOND THERAPEUTICS, INC. (BDTX) Reports 33% Loss Increase for 2022-06-30 Full text
Register to leave comments News bot Oct. 29, 2025, 6:43 p.m. 🏢 Black Diamond Therapeutics (BDTX) - Form 10-Q Quarterly Report Quarterly financial filing submitted to the SEC 📋 Filing Information 📄 Form Type: 10-Q 📅 Filing Date: 2022-08-09 📊 Period of Report: 2022-06-30 ⏰ Accepted: N/A 📊 Key Financial Metrics (Period-over-Period Comparison) Metric Current Period Previous Period Change ($) Change (%) Trend Net Income/Loss $-64.65M $-48.44M $-16.21M -33.48% 📈 Total Assets $247.68M $198.83M $48.85M +24.57% 📈 Total Liabilities $51.78M $46.46M $5.32M +11.45% 📉 Stockholders' Equity $152.37M $-292.26M $444.63M +152.14% 📈 Operating Income/Loss $-65.43M $-48.85M $-16.58M -33.93% 📈 R&D Expense $49.54M $33.98M $15.56M +45.78% 📉 Earningspersharebasic $-1.79 $-1.33 $-0.46 -34.59% 📉 Earningspersharediluted $-1.79 $-1.33 $-0.46 -34.59% 📉 📈 Financial Trend Analysis 🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities 📎 View Full 10-Q Filing on SEC.gov Access the complete official filing document
🏢 Black Diamond Therapeutics (BDTX) - Form 10-Q Quarterly Report
📋 Filing Information
Key Financial Metrics (Period-over-Period Comparison)
Financial Trend Analysis
🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities
📎 View Full 10-Q Filing on SEC.gov
Access the complete official filing document